Remdesivir Clinical Trials
https://www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trials
https://www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trials
The remdesivir clinical trial program was designed to answer multiple scientific questions in parallel, to rapidly evaluate the potential for remdesivir to treat COVID-19 patients.
Gocovri Prescribing Information
https://www.gocovrihcp.com/pdf/Gocovri_Prescribing_Information.pdf
https://www.gocovrihcp.com/pdf/Gocovri_Prescribing_Information.pdf
Gocovri Prescribing Information, PI, Parkinson Disease, PD
U.S. FDA Approves Evofem Biosciences' Phexxi™ (lactic acid, citric acid and potassium bitartrate), the First and Only Non-Hormonal Prescription Gel for the Prevention of Pregnancy
https://evofem.investorroom.com/2020-05-22-U-S-FDA-Approves-Evofem-Biosciences-Phexxi-TM-lactic-acid-citric-acid-and-potassium-bitartrate-the-First-and-Only-Non-Hormonal-Prescription-Gel-for-the-Prevention-of-Pregnancy
https://evofem.investorroom.com/2020-05-22-U-S-FDA-Approves-Evofem-Biosciences-Phexxi-TM-lactic-acid-citric-acid-and-potassium-bitartrate-the-First-and-Only-Non-Hormonal-Prescription-Gel-for-the-Prevention-of-Pregnancy
Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that the U.S. Food and Drug Administration (FDA) has approved Phexxi™ (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.
Gocovri Clinical Data
https://www.gocovrihcp.com/clinical-data/
Gocovrihcp.com
https://www.gocovrihcp.com/clinical-data/
Gocovrihcp.com
May 27th, 2020 - The efficacy and safety of GOCOVRI® 274 mg were evaluated in two Phase 3, randomized, placebo-controlled trials
Lisinopril Drug Facts & Guidance
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019777s054lbl.pdf
FDA
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019777s054lbl.pdf
FDA
Guidance for Industry: Levothyroxine Sodium Tablets — In Vivo Pharmacokinetic and Bioavailability Studies and In Vitro Dissolution Testing
https://www.fda.gov/media/71591/download
FDA
https://www.fda.gov/media/71591/download
FDA
Early indicators: Investigational convalescent plasma is safe for patients with COVID-19
https://newsnetwork.mayoclinic.org/discussion/early-indicators-investigational-convalescent-plasma-is-safe-for-patients-with-covid-19/
https://newsnetwork.mayoclinic.org/discussion/early-indicators-investigational-convalescent-plasma-is-safe-for-patients-with-covid-19/
Mayo Clinic and collaborators today reported safety data on the first 5,000 hospitalized patients transfused with investigational convalescent plasma as part of the Food and Drug Administration’s national Expanded Access Program (EAP) for COVID-19. The early indicators suggest experimental convalescent plasma is safe in treating severely ill patients. At this time, convalescent plasma is the on...
Now Approved PHESGO™
https://www.phesgo.com/hcp.html
https://www.phesgo.com/hcp.html
Info on PHESGO™(pertuzumab/trastuzumab/hyaluronidase-zzxf), See Safety & Boxed Warning. Newly Approved Treatment · Get Info on Dosing · Downloads Available Types: Prescribing Info, Product Guide, Downloadable Brochure
Dojolvi™ (triheptanoin) oral liquid | Ultragenyx
https://www.dojolvi.com/
https://www.dojolvi.com/
Dojolvi is indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).
FINTEPLA® (fenfluramine) oral solution, CIV | For Dravet ...
https://www.finteplahcp.com/
https://www.finteplahcp.com/
FINTEPLA is a prescription medicine used to treat the seizures associated with Dravet syndrome in patients 2 years of age and older. FINTEPLA is a federally controlled substance (C-IV) because it contains fenfluramine. Keep FINTEPLA in a safe place to prevent misuse, abuse, and protect it from theft.
MYCAPSSA® (octreotide) Oral - Capsules Is Now FDA-Approved
https://hcp.mycapssa.com/
https://hcp.mycapssa.com/
MYCAPSSA® (octreotide) delayed-release oral capsules is the first and only FDA-approved oral somatostatin analog (SSA) for appropriate patients with acromegaly, providing effective and consistent biochemical control, while freeing patients from the burden of injections.
INQOVI® (decitabine and cedazuridine) tablets | Now Approved
https://www.inqovi.com/
https://www.inqovi.com/
INQOVI is the first and only oral hypomethylating agent (HMA) indicated for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic ...
Find Safety, PI, Boxed Warning - Now Approved - HCP Site
https:// www.oriahnnhcp.com/
https:// www.oriahnnhcp.com/
ORIAHNN® (elagolix/estradiol/norethindrone acetate and elagolix). View Dosing Information. View Safety Information. Financial Support Info. Official HCP Site.
Gimoti™ (metoclopramide) - Nasal Spray
https://www.gimotirx.com/
https://www.gimotirx.com/
Learn about FDA-approved Gimoti. See Safety and Boxed Warning. Get updates and read about Gimoti, a different formulation of metoclopramide. Prescribing Information. Press Release. Important Safety Info.
Qwo™ Is Now FDA Approved - Endo Aesthetics
https://www.Qwo.com/Now/FDA-Approved
https://www.Qwo.com/Now/FDA-Approved
Qwo™ (collagenase clostridium histolyticum-aaes) Is Now FDA Approved. Check Out The Press Release & Sign Up For More Information From Endo Aesthetics Today. Official Product Site · Sign Up For Updates · Indication
FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma
https://www.fda.gov/drugs/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma
FDA
https://www.fda.gov/drugs/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma
FDA
Jul 23rd, 2020 - The Food and Drug Administration granted accelerated approval to brexucabtagene autoleucel (TECARTUS, Kite, a Gilead Company), a CD19-directed genetically modified autologous T cell immunotherapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
XYWAV™ Coming Soon - Treatment Information
https://xywav.com/hcp/
https://xywav.com/hcp/
(Calcium, Magnesium, Potassium & Sodium Oxybates). See Prescribing Info and BOXED Warning. Discover XYWAV Coming Soon. Sign Up To Receive Treatment and Safety Information Today. Availability Updates. Sign Up. Safety Information. Medication Guide.
FDA-Approved Treatment - TECARTUS™ - tecartus.com
https://www.tecartus.com/hcp
https://www.tecartus.com/hcp
(Brexucabtagene Autoleucel) Visit Site To Learn More & Read Important Warnings. Download The Medication Guide And Find Your Nearest Treatment Center. Important Warnings. Download Med Guide. Find A Center.
Blenrep - Official HCP Website - View Prescribing Information
https://www.blenrephcp.com/
https://www.blenrephcp.com/
HCPs - Learn About Now Approved BLENREP (belantamab mafodotin-blmf). View Boxed Warning.
MONJUVI™ (tafasitamab-cxix) - Official HCP Website
https://www.monjuvihcp.com/
https://www.monjuvihcp.com/
Learn More About MONJUVI, FDA-approved and Now Available. Visit the Official Site Now. Learn About Treatment. Treatment Calendar. Now Approved.
